FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122783505> ?p ?o ?g. }

• W2122783505 endingPage "737" @default.
• W2122783505 startingPage "727" @default.
• W2122783505 abstract "This randomized, controlled trial evaluated the effect of darbepoetin alfa on hospitalization days, transfusion requirements, hemoglobin levels, and fatigue in patients with anemia of cancer (AOC). Eligible patients were anemic (hemoglobin <or=11 g/dl) due to cancer, >or=18 years old, and had not received chemotherapy or radiotherapy within 4 weeks of study screening. Patients were randomized 4:1 to receive darbepoetin alfa, 3.0 microg/kg every 2 weeks (Q2W) (n = 226), or observation only for 12 weeks (n = 59), followed by an optional 9 weeks of darbepoetin alfa, 3.0 microg/kg Q2W. Endpoints were compared between the two treatment arms at week 13. A planned interim analysis indicated that assumptions regarding hospitalization in the study design were incorrect, so the study was terminated early. Therefore, results for the primary endpoint should be interpreted cautiously. The hospitalization rate was similar (0.5 days) for both the darbepoetin alfa and observation groups (p = .73). Transfusion incidence (weeks 5-12) was significantly lower for darbepoetin alfa patients (8%) than for observation patients (22%) (p = .0092). By week 13, hemoglobin increased by 2.1 g/dl in patients receiving darbepoetin alfa, compared with 0.1 g/dl in the observation group p < .0001. Hemoglobin improvements were paralleled by an increase in Functional Assessment of Cancer Therapy-Fatigue score (mean change in score at week 13: darbepoetin alfa, 6.0; observation, 2.2; p < .05). Darbepoetin alfa Q2W can significantly improve hemoglobin levels and reduce transfusion requirements in patients with AOC, resulting in significant improvements in health-related quality of life." @default.
• W2122783505 created "2016-06-24" @default.
• W2122783505 creator A5027801794 @default.
• W2122783505 creator A5034876741 @default.
• W2122783505 creator A5046657704 @default.
• W2122783505 creator A5054286974 @default.
• W2122783505 creator A5071524213 @default.
• W2122783505 creator A5074682950 @default.
• W2122783505 creator A5085484066 @default.
• W2122783505 date "2007-06-01" @default.
• W2122783505 modified "2023-10-10" @default.
• W2122783505 title "Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial" @default.
• W2122783505 cites W1821554592 @default.
• W2122783505 cites W1867073577 @default.
• W2122783505 cites W1884165293 @default.
• W2122783505 cites W1885881044 @default.
• W2122783505 cites W1888844917 @default.
• W2122783505 cites W1996698172 @default.
• W2122783505 cites W2002189627 @default.
• W2122783505 cites W2012264968 @default.
• W2122783505 cites W2024159843 @default.
• W2122783505 cites W2035715804 @default.
• W2122783505 cites W2063966710 @default.
• W2122783505 cites W2081203495 @default.
• W2122783505 cites W2089524549 @default.
• W2122783505 cites W2091061603 @default.
• W2122783505 cites W2093666912 @default.
• W2122783505 cites W2120940824 @default.
• W2122783505 cites W2123200029 @default.
• W2122783505 cites W2125044142 @default.
• W2122783505 cites W2146353390 @default.
• W2122783505 cites W2150023617 @default.
• W2122783505 cites W2159283488 @default.
• W2122783505 cites W2163830215 @default.
• W2122783505 cites W2170650765 @default.
• W2122783505 cites W2340124568 @default.
• W2122783505 cites W3140909591 @default.
• W2122783505 doi "https://doi.org/10.1634/theoncologist.12-6-727" @default.
• W2122783505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17602062" @default.
• W2122783505 hasPublicationYear "2007" @default.
• W2122783505 type Work @default.
• W2122783505 sameAs 2122783505 @default.
• W2122783505 citedByCount "27" @default.
• W2122783505 countsByYear W21227835052012 @default.
• W2122783505 countsByYear W21227835052013 @default.
• W2122783505 countsByYear W21227835052014 @default.
• W2122783505 countsByYear W21227835052016 @default.
• W2122783505 countsByYear W21227835052018 @default.
• W2122783505 countsByYear W21227835052022 @default.
• W2122783505 crossrefType "journal-article" @default.
• W2122783505 hasAuthorship W2122783505A5027801794 @default.
• W2122783505 hasAuthorship W2122783505A5034876741 @default.
• W2122783505 hasAuthorship W2122783505A5046657704 @default.
• W2122783505 hasAuthorship W2122783505A5054286974 @default.
• W2122783505 hasAuthorship W2122783505A5071524213 @default.
• W2122783505 hasAuthorship W2122783505A5074682950 @default.
• W2122783505 hasAuthorship W2122783505A5085484066 @default.
• W2122783505 hasBestOaLocation W21227835051 @default.
• W2122783505 hasConcept C120665830 @default.
• W2122783505 hasConcept C121332964 @default.
• W2122783505 hasConcept C121608353 @default.
• W2122783505 hasConcept C126322002 @default.
• W2122783505 hasConcept C141071460 @default.
• W2122783505 hasConcept C168563851 @default.
• W2122783505 hasConcept C203092338 @default.
• W2122783505 hasConcept C2776164570 @default.
• W2122783505 hasConcept C2778248108 @default.
• W2122783505 hasConcept C2778917026 @default.
• W2122783505 hasConcept C2781404941 @default.
• W2122783505 hasConcept C61511704 @default.
• W2122783505 hasConcept C61943457 @default.
• W2122783505 hasConcept C71924100 @default.
• W2122783505 hasConceptScore W2122783505C120665830 @default.
• W2122783505 hasConceptScore W2122783505C121332964 @default.
• W2122783505 hasConceptScore W2122783505C121608353 @default.
• W2122783505 hasConceptScore W2122783505C126322002 @default.
• W2122783505 hasConceptScore W2122783505C141071460 @default.
• W2122783505 hasConceptScore W2122783505C168563851 @default.
• W2122783505 hasConceptScore W2122783505C203092338 @default.
• W2122783505 hasConceptScore W2122783505C2776164570 @default.
• W2122783505 hasConceptScore W2122783505C2778248108 @default.
• W2122783505 hasConceptScore W2122783505C2778917026 @default.
• W2122783505 hasConceptScore W2122783505C2781404941 @default.
• W2122783505 hasConceptScore W2122783505C61511704 @default.
• W2122783505 hasConceptScore W2122783505C61943457 @default.
• W2122783505 hasConceptScore W2122783505C71924100 @default.
• W2122783505 hasIssue "6" @default.
• W2122783505 hasLocation W21227835051 @default.
• W2122783505 hasLocation W21227835052 @default.
• W2122783505 hasOpenAccess W2122783505 @default.
• W2122783505 hasPrimaryLocation W21227835051 @default.
• W2122783505 hasRelatedWork W2012498878 @default.
• W2122783505 hasRelatedWork W2061049097 @default.
• W2122783505 hasRelatedWork W2068549379 @default.
• W2122783505 hasRelatedWork W2113406202 @default.
• W2122783505 hasRelatedWork W2121864589 @default.
• W2122783505 hasRelatedWork W2139586631 @default.
• W2122783505 hasRelatedWork W2241867744 @default.

• next